Abstract: Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.

Abstract: The present invention relates to pesticidal and parasiticidal isoxazoline of formula (I) and salts thereof: wherein variables R1, P, Y and Q are described herein are as defined in the description. The invention also relates to parasiticidal and pesticidal compositions comprising the isoxazoline compounds of formula (I), processes for their preparation and their uses to prevent or treat parasitic infections or infestations in animals and as pesticides.

Abstract: The present invention provides a genus of polycyclic amines that are useful as opioid receptor modulators. The compounds of the invention are useful in both therapeutic and diagnostic methods, including for treating pain, neurological disorders, cardiac disorders, bowel disorders, drug and alcohol addiction, drug overdose, urinary disorders, respiratory disorders, sexual dysfunction, psoriasis, graft rejection or cancer.

Abstract: This application relates to combination compositions for use in treatment of depression, and which can alleviate the anxiogenic side effects of certain antidepressant and antipsychotic medications. Methods for treatment of depression and medicament side effects, particular anxiety, akathisia, and associated suicidality are also described herein.

Abstract: Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.

Abstract: Methods for preparing a PEG composition by co-precipitation of two or more components to produce a substantially homogenous powder. According to some embodiments, the two or more components are at least and partially soluble in a solvent, and at least one component is a functionalized PEG. Contacting the at least two component with the solvent at least partially dissolves the components which are then co-precipitated. The resulting product is substantially homogenous, unlike product made by other methods. The PEG composition may be co-precipitated with additional compounds, such as a colorant like indocyanine green.

Abstract: Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.

Abstract: Liquid oral pilocarpine formulations are described herein. Methods of using the liquid oral pilocarpine formulations are also provided.

Abstract: The present invention relates to a series of novel compounds, methods to prevent or treat viral infections in animals by using the novel compounds and to said novel compounds for use as a medicine, more preferably for use as a medicine to treat or prevent viral infections, particularly infections with RNA viruses, more particularly infections with viruses belonging to the family of the Flaviviridae, and yet more particularly infections with the Dengue virus. The present invention furthermore relates to pharmaceutical compositions or combination preparations of the novel compounds, to the compositions or preparations for use as a medicine, more preferably for the prevention or treatment of viral infections. The invention also relates to processes for preparation of the compounds.

Abstract: The present disclosure is directed to compositions comprising oxymetazoline and methods of stabilizing oxymetazoline compositions for long term storage.

Abstract: Intra-oral formulations comprising soft anticholinergic alkyl esters are useful for treating excessive drooling conditions in subjects, such as humans, suffering from sialorrhea. Preferably, at least one soft anticholinergic ester is provided in an effective amount or concentration in an anhydrous intra-oral formulation that can inhibit excessive drooling resulting from a condition known as sialorrhea.

Abstract: The invention provides an extract of Plectranthus amboinicus (Lour.) Spreng enriching anti-arthritis activity, which is obtained by eluting the crude extract of Plectranthus amboinicus (Lour.) Spreng using 50%˜95% alcoholic solution or solvents such as hexane and/or ethyl acetate. Also provided is a method for treating arthritis comprising such extract.

Abstract: The present invention relates to a compound represented by general formula (I) (wherein, all symbols represent the same meanings as the symbols set forth in the specification), a salt thereof, a solvate thereof, an N-oxide thereof, or a prodrug of any of these. Since the compound has a Brk inhibitory activity, the compound is useful as a drug ingredient for the prevention and/or treatment of Brk-related diseases such as cancer, for example.

Abstract: Disclosed herein are compositions comprising an NSAID such as meloxicam and/or rizatriptan in combination with a cyclodextrin and/or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a Tmax of meloxicam of 3 hours or less.

Abstract: The present application provides, inter alia, a compound of Formula (I): or a pharmaceutically acceptable salt thereof, and methods of use of the compound of Formula (I) for treatment and prevention of cyanide poisoning.

Abstract: Provided are polyphosphazenes and methods of making and using the polyphosphazenes. The polyphosphazenes can be essentially chloride free. The polyphosphazenes can be phosphazene polyacids. The polyphosphazenes can be used as surface coatings, or as adjuvants when combined with antigens.

Abstract: The present invention relates to the use of ruthenium(II) complexes for preparing a medicinal product for treating cancer, particularly cancer comprising cancer stem cells. Said ruthenium complexes are capable of selectively metallating guanine quadruplexes, thus resulting in increased expression of the c-MYC oncogene. This increase in the proportion of c-MYC may promote the differentiation of cancer stem cells.

Abstract: The objective of the present invention is to provide a repellent which has a selectivity. Specifically, the repellent does not cause damage to an Apidae bee but suppresses the aggression of a Vespidae wasp and prevents a Vespidae wasp from coming close and building a nest. Also, the objective of the present invention is to provide a method for repelling a Vespidae wasp. The Vespidae wasp repellent according to the present invention is characterized in comprising a compound represented by the following formula (I) as an active component: wherein R1 is hydrogen atom or the like, X is a C1-4 alkylene group or the like, ? is a substituent, n is an integer of 0 or more and 5 or less.

Abstract: The present disclosure provides compositions having different dissolution profiles. In particular, the compositions are formulated by adjusting the types and/or amounts of excipients and/or surfactants, and the compositions are prepared by spray drying processes.

Abstract: The present invention provides a compound that is highly safe and useful in the prevention, alleviation, and/or treatment of various diseases involving enteropeptidase inhibition and/or trypsin inhibition, a pharmaceutical composition containing the compound, a method for producing the compound, and the like. Specifically, the present invention provides a compound represented by the following general formula (I): [wherein: A1 and A2 each independently represent an inhibitor residue having at least one activity selected from an enteropeptidase inhibitory activity and a trypsin inhibitory activity; and Z represents a spacer that links A1 to A2] or a pharmaceutically acceptable salt thereof.